Bayer Licenses Brenda-Amenda Database for Target Research

Bayer HealthCare gained access to Biobase’s enzyme and metabolism research database, according to a license agreement between the two companies. The Brenda-Amenda database summarizes more than 50 years worth of research in this field. Bayer Healthcare will be using the database for target-based research related to cardiovascular disease.

The new text-mining based Amenda module expands Brenda's enzyme-related reference content five-fold by means of structured access to organism-specific enzyme information, such as statements about tissue affiliation or subcellular localization, from 15 million PubMed articles.

Brenda-Amenda is a relational database that contains manually-curated biochemical and molecular information about more than 83,000 enzymes from 9,800 organisms. To date, Brenda-Amenda contains 500,000 enzyme-ligand correlations, including more than 46,000 different chemical compounds that act as ligands and 34,500 ligand structures.